Abstract
Attempts have been made to find specific antigens for a novel NKT cell subset bearing invariant Vα19-Jα33 TCR α chains (Vα19 NKT cell). Comprehensive examinations revealed substantial antigenic activity in synthetic α- mannosylceramide (ManCer) that was presented by MR1. Structural modification of the sphingosine moiety of α-ManCer improved antigenic activity to enhance either Th1 or Th2 – promoting cytokine production by Vα19 NKT cells. Such α- ManCer analogues will be useful for developing new therapies as immunomodulators.
Keywords: Glycolipid, FTY720, NKT cell, invariant TCR, immunomodulator, non-classical MHC class I
Mini-Reviews in Medicinal Chemistry
Title: Glycolipid Stimulators for NKT Cells Bearing Invariant Vα19-Jα33 TCR α Chains
Volume: 8 Issue: 3
Author(s): M. Shimamura
Affiliation:
Keywords: Glycolipid, FTY720, NKT cell, invariant TCR, immunomodulator, non-classical MHC class I
Abstract: Attempts have been made to find specific antigens for a novel NKT cell subset bearing invariant Vα19-Jα33 TCR α chains (Vα19 NKT cell). Comprehensive examinations revealed substantial antigenic activity in synthetic α- mannosylceramide (ManCer) that was presented by MR1. Structural modification of the sphingosine moiety of α-ManCer improved antigenic activity to enhance either Th1 or Th2 – promoting cytokine production by Vα19 NKT cells. Such α- ManCer analogues will be useful for developing new therapies as immunomodulators.
Export Options
About this article
Cite this article as:
Shimamura M., Glycolipid Stimulators for NKT Cells Bearing Invariant Vα19-Jα33 TCR α Chains, Mini-Reviews in Medicinal Chemistry 2008; 8 (3) . https://dx.doi.org/10.2174/138955708783744119
DOI https://dx.doi.org/10.2174/138955708783744119 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Jaridonin, a Novel Ent-Kaurene Diterpenoid from Isodon rubescens, Inducing Apoptosis via Production of Reactive Oxygen Species in Esophageal Cancer Cells
Current Cancer Drug Targets Indoleamine 2,3-Dioxygenase in Materno-Fetal Interaction
Current Drug Metabolism Therapeutic Indications and Action Mechanisms of Bilirubin: Suggestions from Natural Calculus Bovis
Current Signal Transduction Therapy Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology The Blood-Central Nervous System Barriers Actively Control Immune Cell Entry into the Central Nervous System
Current Pharmaceutical Design New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design From TGF-β to Cancer Therapy
Current Drug Targets The Role of Oligodendrocytes in the Molecular Pathobiology and Potential Molecular Treatment of Cervical Spondylotic Myelopathy
Current Medicinal Chemistry Macrophage Heterogeneity: Relevance and Functional Implications in Atherosclerosis
Current Vascular Pharmacology Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Altered Peptide Ligand Antagonism: From Immune Evasion to Immunotherapy
Drug Design Reviews - Online (Discontinued) Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design